GlassScriptPhysician profile
William R Brown
NPI 1831344001
$10,247.33
in general payments reported to CMS, 2019-2025
34 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,387 · 2020: $1,650 · 2021: $992 · 2022: $1,441 · 2023: $685 · 2024: $1,474 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,051.45 | 2019-2024 | Cardiomems, Dragonfly Opstar |
| Abiomed | $1,530.71 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $977.44 | 2019-2023 | Xarelto |
| Cvrx, INC. | $776.52 | 2020-2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $646.05 | 2019 | |
| Amgen INC. | $533.56 | 2019-2024 | Repatha |
| Atricure, INC. | $383.14 | 2021-2023 | |
| Medtronic, INC. | $363.86 | 2021-2024 | Venaseal, Linq II |
| Novartis Pharmaceuticals Corporation | $331.27 | 2019-2025 | |
| Boston Scientific Corporation | $289.55 | 2019-2024 | Watchman Flx, Watchman |
| Sanofi-Aventis U.S. LLC | $249.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $240.80 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $193.36 | 2019-2024 | Farxiga |
| Irhythm Technologies, INC. | $179.96 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.74 | 2019-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $160.79 | 2022 | |
| Shockwave Medical, INC | $151.37 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $133.54 | 2019 | |
| Silk Road Medical, INC. | $124.62 | 2019 | |
| Cardiofocus, INC. | $97.89 | 2020 | |
| Amarin Pharma, INC. | $95.50 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.58 | 2024-2025 | Lifevest |
| Pfizer INC. | $89.26 | 2019-2022 | |
| Inari Medical, INC. | $84.37 | 2019 | |
| Medtronic Vascular, INC. | $61.23 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.97 | 2019-2020 | |
| Esperion Therapeutics, INC. | $45.21 | 2020-2024 | Nexletol |
| Tactile Systems Technology INC | $26.82 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Arbor Pharmaceuticals, INC. | $26.32 | 2020-2021 | |
| Akcea Therapeutics, INC. | $21.41 | 2019 | |
| Althera Pharmaceuticals LLC | $21.02 | 2022 | |
| Gilead Sciences, INC. | $19.18 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.87 | 2019 | |
| Altathera Pharmaceuticals LLC | $12.99 | 2023 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.